EGPA treatment market to reach $2.22B by 2030 at 9.6% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Eosinophilic Granulomatosis With Polyangiitis Treatment Market In 2026, And How Will Its Value Evolve By 2030?
The market for eosinophilic granulomatosis with polyangiitis treatments has experienced robust expansion in recent times. Projections indicate it will expand from $1.41 billion in 2025 to reach $1.54 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 9.8%. Historically, this growth has been driven by factors such as increased autoimmune disease awareness, dependence on corticosteroids, enhancements in rare disease diagnosis, the availability of hospital-based immunology care, and the necessity for effective inflammation management.
The eosinophilic granulomatosis with polyangiitis treatment market is projected to experience substantial expansion in the coming years. This market is set to reach $2.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Factors contributing to this growth during the forecast period include advancements in biologic drugs, increased funding for rare diseases, the development of personalized autoimmune treatments, the expansion of specialty clinics, and the implementation of early intervention protocols. Key trends anticipated for this period encompass the growing adoption of targeted biologic therapies, a heightened emphasis on rare autoimmune conditions, an increase in long-term immunosuppressive treatments, the broadening of specialized autoimmune care, and a focus on achieving early disease control.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Drivers Are Fueling The Growth Of The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
The growing occurrence of asthma among older adults is projected to stimulate the expansion of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market. Asthma, a condition characterized by swollen and narrowed airways that hinder breathing, is becoming more common in the aging population due to a natural decline in lung function. As the lungs lose elasticity and airway muscles weaken with age, breathing becomes more challenging, making older individuals more prone to inflammation and respiratory illnesses. This increase in asthma cases among the elderly leads to greater screening for linked conditions such as EGPA, which frequently originates with asthma, thereby escalating the need for its treatment. For example, in 2024, the Global Initiative for Asthma, a US-based medical organization, reported that asthma is a widespread chronic non-communicable disease affecting over 260 million people globally and causing more than 450,000 fatalities each year. Consequently, the rising prevalence of asthma among the aging demographic is a key factor propelling the growth of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market. The growing occurrence of allergic reactions is anticipated to boost the expansion of the eosinophilic granulomatosis with polyangiitis treatment market moving forward. The prevalence of allergic reactions is increasing due to rising levels of air pollution. Airborne irritants such as smoke, dust, and various chemicals can stimulate the immune system, thereby heightening individuals’ sensitivity to allergens. As allergic reactions become more widespread, a greater number of people develop conditions associated with an overactive immune system, including eosinophilic granulomatosis with polyangiitis. This situation consequently drives up the demand for effective treatments aimed at managing inflammation and associated symptoms. For illustration, data from PubMed, the US-based National Institutes of Health, indicated in 2024 that the most frequently reported allergic comorbidities among patients with food allergies were atopic dermatitis (48%), asthma (46%), and allergic rhinitis (39%). Furthermore, a significant portion of patients, 42%, experienced more than one food-related allergic reaction annually, with 46% enduring food-induced anaphylaxis. Therefore, the rising incidence of allergic reactions is a significant factor propelling the growth of the eosinophilic granulomatosis with polyangiitis treatment market.
How Is The Eosinophilic Granulomatosis With Polyangiitis Treatment Market Broken Down By Segment Categories?
The eosinophilic granulomatosis with polyangiitis treatment market covered in this report is segmented –
1) By Drug Class: Steroids, Immunosuppressant, Biologics, Immune Globulins
2) By Route Of Administration: Oral, Intravenous, Intramuscular
3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Drug Stores, Retail Pharmacies
4) By End User: Hospitals, Clinics, Home Healthcare
Subsegments:
1) By Steroids: Glucocorticoids, Mineralocorticoids
2) By Immunosuppressants: Calcineurin Inhibitors, Antimetabolites, Alkylating Agents
3) By Biologics: Interleukin Inhibitors, Monoclonal Antibodies, TNF-alpha Inhibitors
4) By Immune Globulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
What Trends Are Influencing The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
Key players in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market are actively engaged in clinical trials to evaluate the safety and efficacy of both current and emerging therapies. The objective of these clinical trials is to expand treatment alternatives, obtain regulatory clearances, and enhance patient outcomes. For example, in September 2024, AstraZeneca, a pharmaceutical and biotechnology firm based in the UK, disclosed positive findings from its MANDARA Phase III trial. This trial demonstrated that Fasenra (benralizumab) effectively induces remission in patients diagnosed with eosinophilic granulomatosis with polyangiitis. The results further indicated that benralizumab achieved remission rates similar to those of mepolizumab, while also lessening the requirement for oral glucocorticoids. This progress marks an important stride towards more focused and steroid-sparing treatment methodologies for eosinophilic granulomatosis with polyangiitis.
Which Players Are Present In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market Space?
Major companies operating in the eosinophilic granulomatosis with polyangiitis treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Roche Holding AG, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Intas Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Biogen Inc., Fresenius Kabi, Amgen Inc., Sun Pharmaceutical Industries, Apotex Inc., Cipla Ltd., Dr. Reddy’s Laboratories, Lupin Limited, Alkem Laboratories, NS Pharma
Get The Full Eosinophilic Granulomatosis With Polyangiitis Treatment Market Report:
Which Region Represents The Largest Share Of The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
North America was the largest region in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic granulomatosis with polyangiitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Eosinophilic Granulomatosis With Polyangiitis Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market 2026, By The Business Research Company
Polyclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report
Nasal Polyps Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/nasal-polyps-treatment-global-market-report
Chronic Rhinosinusitis With Nasal Polyps Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
